Developer docs
API playgroundTry for free, no card

Search company profiles

Encapsulate

Full company profile

uuid0000bem

Namestring
Encapsulate
Legal namestring
Encapsulate, Inc.
Websiteurl
encapsulate.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Encapsulate, Inc. is a privately held precision diagnostics company developing automated tumor-on-a-chip systems for personalized cancer therapy. Founded in 2019 by graduate students at the University of Connecticut, the company grows patient-derived microtumors from biopsies on microfluidic biochips and screens them against clinical chemotherapy regimens, generating personalized treatment recommendations in under seven days. The company serves three primary customer segments: oncologists and cancer centers seeking functional validation of optimal chemotherapy regimens for individual patients, pharmaceutical companies requiring patient-derived preclinical models for drug testing, patient stratification, and IND submission support, and academic researchers studying cancer biology and treatment response.

The platform is built on patented microfluidic biochip technology that preserves the native tumor microenvironment — including stromal cells, extracellular matrix, and immune cell interactions — to create hundreds of replicates from a single patient biopsy. The system integrates programmable microfluidics for controlled media exchange and drug dosing, high-resolution imaging pipelines, and AI/ML-based quantitative phenotyping for predictive modeling. Three product lines are in development: the core Tumor-on-a-Chip System for chemotherapy selection, the Metastasis-on-a-Chip platform (NASA InSPA-funded) for modeling cancer metastasis under microgravity conditions, and an Automated Chemotherapy Selection Platform (NSF SBIR Phase II-funded) focused on pancreatic and colorectal cancers. Encapsulate's technology has been validated aboard the International Space Station, with cargo launched via SpaceX CRS-30 in March 2024 and operations executed through partner Space Tango across three joint missions.

Encapsulate generates revenue through fee-for-service engagements with pharmaceutical companies (preclinical drug testing, patient stratification, combination screening, IND submission support), clinical testing services for cancer centers, and biobank access for researchers, with custom multi-year contracts priced per study scope. The company also derives material non-dilutive revenue from government research grants, including the $3.63 million NASA InSPA Phase 1 grant (July 2025) and $1.25 million NSF SBIR Phase II grant (July 2025), and closed a $1.8 million oversubscribed seed round in November 2024 led by Blackwood Healthcare Breakthroughs, Ambit Health Ventures, and CT Innovations. Commercial clinical operations are anchored by direct partnerships with Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, UConn Health, and Hartford HealthCare. The company is headquartered at UConn's Technology Incubator Program facility in Farmington, Connecticut, and operates with a 15-25 person team led by co-founders Armin Rad, PhD (CEO) and Leila Daneshmandi, PhD (COO), with Reza Amin as third co-founder.

Short descriptiontext

Encapsulate develops automated tumor-on-a-chip systems that grow patient-derived microtumors from biopsies and screen them against chemotherapy regimens, delivering personalized treatment recommendations to oncologists, pharmaceutical R&D teams, and cancer centers within seven days.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFarmington, United States
HQ citystring
Farmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tumor-on-a-chip technology, precision cancer diagnostics, patient-derived organoids, preclinical drug screening, microfluidic biochips
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Precision Oncology Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Drug Testing Services
TypeTransaction Fee
Description

Fee-for-service model where pharmaceutical companies engage Encapsulate to test their drug compounds on patient-derived tumor models for preclinical studies, patient stratification, and IND submissions.

encapsulate.bio
2Clinical Testing Services
TypeProfessional Services
Description

Direct testing services for clinicians and cancer centers where patient biopsies are screened against treatment regimens to generate personalized treatment recommendations.

encapsulate.bio
3Government Research Grants
TypeManaged Services
Description

Non-dilutive funding from NASA InSPA ($3.63M), NSF SBIR Phase II ($1.25M), and other government grants supporting R&D activities.

encapsulate.bio
4Biobank and Data Services
TypeData Monetisation
Description

Access to patient biobank with hundreds of patients having known genetic mutations, clinical and lab-based response profiles for research purposes.

encapsulate.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom engagement models based on study scope
ModelOtherBilling cadenceMulti-year contract
Notes

Engagement models include: Sample-to-Data (patient biopsies provided), Model-to-Data (PDOs or tumor samples provided), Drug Testing Partnerships (compounds provided), and Custom Study Design. Pricing varies by cancer type, number of compounds tested, and study complexity.

encapsulate.bio
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Encapsulate develops an automated tumor-on-a-chip platform that grows patient-derived microtumors from biopsy or surgical specimens and screens them against clinical treatment regimens to produce patient-specific chemotherapy response profiles. The platform is also offered to pharmaceutical companies for preclinical drug efficacy and lead-optimization studies, and supports a novel microgravity-based metastasis research program on the International Space Station. End-to-end turnaround for clinical response profiles is delivered in under 7 days, with screening capability spanning 50+ FDA-approved and investigational chemotherapeutic agents.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Personalized treatment recommendations delivered in under 7 days
+5 more records
Product overview1 text field

Encapsulate offers an integrated tumor-on-a-chip platform for personalized cancer therapy. The core offering consists of the Tumor-on-a-Chip System, which screens patient-derived microtumors against clinical treatment regimens to generate personalized insights in under 7 days. This is complemented by the Metastasis-on-a-Chip platform (NASA InSPA funded) for microgravity-based cancer metastasis modeling, and the Automated Chemotherapy Selection Platform (NSF SBIR funded) for pancreatic and colorectal cancers. The company also provides services for pharmaceutical companies, clinicians, and patients, leveraging space-based research through ISS experiments to enhance the biological fidelity of their tumor models.

Product and service4 records
1Automated Tumor-on-a-Chip Platform
CategoryPrecision Oncology Diagnostics / Preclinical Drug Screening
Description

End-to-end automated microfluidic platform that cultures patient-derived microtumors from biopsy or surgical specimens and screens them against 50+ FDA-approved and investigational chemotherapeutic regimens to produce personalized response profiles within 7 days; sold to pharmaceutical companies for preclinical screening and to oncology providers for personalized chemotherapy selection.

2Personalized Chemotherapy Selection Service
CategoryClinical Oncology Diagnostics
Description

Clinical service in which Encapsulate receives a patient's tumor specimen, screens it against the chemotherapeutic library on the tumor-on-a-chip platform, and returns a ranked, patient-specific treatment response profile to inform the treating oncologist's regimen selection.

3Pharmaceutical Preclinical Drug Screening Service
CategoryPharmaceutical Preclinical Services
Description

Service for pharmaceutical R&D teams in which Encapsulate runs investigational and approved oncology compounds through patient-derived microtumors on the tumor-on-a-chip platform, delivering preclinical efficacy, dose-response, and lead-optimization data with reduced turnaround compared to manual organoid workflows.

4Metastasis-on-a-Chip Microgravity Research Program
CategoryTranslational Metastasis Research
Description

Research program that extends the tumor-on-a-chip platform into microgravity conditions aboard the International Space Station to study tumor metastasis and behavior in a uniquely low-shear environment, offered to academic, translational, and pharmaceutical partners studying metastasis and drug resistance.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-08
Description

In-orbit implementation partner for deploying and operating experiments aboard the International Space Station. Marks their third mission together. Space Tango provides flight implementation services for Encapsulate's automated biochip platform for space-based cancer research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Clinical partner for retrospective and prospective clinical studies in pancreatic and colorectal cancers as part of NSF SBIR Phase II grant. Key investigators include Dr. Tiago Biachi and Dr. Sarah Hoffe.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Clinical partner for retrospective and prospective clinical studies in pancreatic and colorectal cancers. Dr. Danny Khalil serves on Clinical Advisory Board.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Primary clinical partner and headquarters location. Hosts Encapsulate in Technology Incubation Program. Dr. John Birk serves on Clinical Advisory Board.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Selected into 2019 MassChallenge Boston program as one of top 9% of applicants worldwide. Zero-equity startup accelerator providing mentorship, corporate partners, and co-working space.

6NASA
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NASA provides access to microgravity environments through the International Space Station and supports through programs like In Space Production Applications (InSPA). NASA awarded $3.63M InSPA Phase 1 grant for Metastasis-on-a-Chip development.

encapsulate.bio
7International Space Station National Laboratory (ISSNL)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ISSNL provides access to the ISS for microgravity research and has featured Encapsulate's work multiple times. Encapsulate launched cargo to the ISS aboard SpaceX CRS-30 mission.

encapsulate.bio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical partner and founding partner of Digital Health CT accelerator. Dr. Alvaro Menendez serves on Clinical Advisory Board. Partnered for clinical validation studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-sponsor of Technology in Space Prize with ISS National Lab. Boeing and ISS NL have collectively awarded 27 projects and more than $4.5 million through the prize since 2012.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Andre Levchenko serves on Scientific Advisory Board, providing academic expertise in biomedical engineering.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MedTech accelerator program in Hartford with founding partners including Hartford HealthCare, Trinity College, UConn School of Business and Technology Commercialization Services, and CTNext.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch organ-on-a-chip company providing microfluidic 3D cell culture platforms including tumor models for drug screening. Comparable technology architecture and pharma services orientation.

TypeDirect peer
Description

Functional precision oncology company providing patient-derived tumor models for drug response prediction and preclinical services. Direct overlap in ex vivo chemo-response testing services.

TypeEmerging player
Description

AI-enabled biology platform combining high-throughput experimentation with machine learning for drug discovery. Comparable in applying AI/ML to biological data, though focused upstream on therapeutic discovery rather than patient diagnostics.

TypeDirect peer
Description

Multi-organ-chip company developing microphysiological systems for preclinical testing. Comparable microfluidic platform with broader multi-organ emphasis, including oncology-relevant applications.

TypeDirect peer
Description

Leader in organ-on-a-chip technology for drug discovery and disease modeling, including cancer applications. Directly comparable in core microfluidic organoid platform approach, though broader in tissue types and with deeper commercial scale.

TypeBroad incumbent
Description

Large preclinical CRO offering extensive oncology drug development and patient-derived model services. Incumbent player in the same pharma services budget, with broader portfolio and established scale.

TypeDirect peer
Description

Provider of patient-derived xenograft models and tumor-based services for personalized oncology and pharma R&D. Adjacent approach (in vivo PDX) competing for the same functional precision oncology and preclinical services budget.

TypeDirect peer
Description

Functional precision oncology company using 3D patient-derived cell culture to predict cancer therapy response ex vivo. Most direct competitor in the patient-derived tumor organoid chemo-response prediction space Encapsulate targets.

9CN Bio
TypeDirect peer
Description

Organ-on-a-chip and microphysiological systems provider for preclinical drug development. Competes in the same microfluidic organoid platform category with pharma R&D customers.

10Hurel Corporation
TypeEmerging player
Description

Microfluidic cell-based assay technology company serving preclinical drug development with emphasis on liver and oncology applications. Comparable microfluidic technology and pharma services customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Encapsulate

Precision Oncology Diagnosticsencapsulate.bio

Encapsulate develops automated tumor-on-a-chip systems that grow patient-derived microtumors from biopsies and screen them against chemotherapy regimens, delivering personalized treatment recommendations to oncologists, pharmaceutical R&D teams, and cancer centers within seven days.

What Encapsulate does

Encapsulate, Inc. is a privately held precision diagnostics company developing automated tumor-on-a-chip systems for personalized cancer therapy. Founded in 2019 by graduate students at the University of Connecticut, the company grows patient-derived microtumors from biopsies on microfluidic biochips and screens them against clinical chemotherapy regimens, generating personalized treatment recommendations in under seven days. The company serves three primary customer segments: oncologists and cancer centers seeking functional validation of optimal chemotherapy regimens for individual patients, pharmaceutical companies requiring patient-derived preclinical models for drug testing, patient stratification, and IND submission support, and academic researchers studying cancer biology and treatment response.

The platform is built on patented microfluidic biochip technology that preserves the native tumor microenvironment — including stromal cells, extracellular matrix, and immune cell interactions — to create hundreds of replicates from a single patient biopsy. The system integrates programmable microfluidics for controlled media exchange and drug dosing, high-resolution imaging pipelines, and AI/ML-based quantitative phenotyping for predictive modeling. Three product lines are in development: the core Tumor-on-a-Chip System for chemotherapy selection, the Metastasis-on-a-Chip platform (NASA InSPA-funded) for modeling cancer metastasis under microgravity conditions, and an Automated Chemotherapy Selection Platform (NSF SBIR Phase II-funded) focused on pancreatic and colorectal cancers. Encapsulate's technology has been validated aboard the International Space Station, with cargo launched via SpaceX CRS-30 in March 2024 and operations executed through partner Space Tango across three joint missions.

Encapsulate generates revenue through fee-for-service engagements with pharmaceutical companies (preclinical drug testing, patient stratification, combination screening, IND submission support), clinical testing services for cancer centers, and biobank access for researchers, with custom multi-year contracts priced per study scope. The company also derives material non-dilutive revenue from government research grants, including the $3.63 million NASA InSPA Phase 1 grant (July 2025) and $1.25 million NSF SBIR Phase II grant (July 2025), and closed a $1.8 million oversubscribed seed round in November 2024 led by Blackwood Healthcare Breakthroughs, Ambit Health Ventures, and CT Innovations. Commercial clinical operations are anchored by direct partnerships with Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, UConn Health, and Hartford HealthCare. The company is headquartered at UConn's Technology Incubator Program facility in Farmington, Connecticut, and operates with a 15-25 person team led by co-founders Armin Rad, PhD (CEO) and Leila Daneshmandi, PhD (COO), with Reza Amin as third co-founder.

Encapsulate firmographics

Firmographics
Name
Encapsulate
Legal name
Encapsulate, Inc.
Website
https://encapsulate.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Encapsulate develops automated tumor-on-a-chip systems that grow patient-derived microtumors from biopsies and screen them against chemotherapy regimens, delivering personalized treatment recommendations to oncologists, pharmaceutical R&D teams, and cancer centers within seven days.
Ownership category
akta.pro rank

Encapsulate industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Tumor-on-a-chip technology
  • Precision cancer diagnostics
  • Patient-derived organoids
  • Preclinical drug screening
  • Microfluidic biochips

Where Encapsulate is headquartered

Location

Headquarters

HQ city
Farmington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Encapsulate business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Drug Testing Services: Fee-for-service model where pharmaceutical companies engage Encapsulate to test their drug compounds on patient-derived tumor models for preclinical studies, patient stratification, and IND submissions.
  2. Clinical Testing Services: Direct testing services for clinicians and cancer centers where patient biopsies are screened against treatment regimens to generate personalized treatment recommendations.
  3. Government Research Grants: Non-dilutive funding from NASA InSPA ($3.63M), NSF SBIR Phase II ($1.25M), and other government grants supporting R&D activities.
  4. Biobank and Data Services: Access to patient biobank with hundreds of patients having known genetic mutations, clinical and lab-based response profiles for research purposes.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom engagement models based on study scope

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Encapsulate product offering

Product offering

Core offering

Encapsulate develops an automated tumor-on-a-chip platform that grows patient-derived microtumors from biopsy or surgical specimens and screens them against clinical treatment regimens to produce patient-specific chemotherapy response profiles. The platform is also offered to pharmaceutical companies for preclinical drug efficacy and lead-optimization studies, and supports a novel microgravity-based metastasis research program on the International Space Station. End-to-end turnaround for clinical response profiles is delivered in under 7 days, with screening capability spanning 50+ FDA-approved and investigational chemotherapeutic agents.

Product overview

Encapsulate offers an integrated tumor-on-a-chip platform for personalized cancer therapy. The core offering consists of the Tumor-on-a-Chip System, which screens patient-derived microtumors against clinical treatment regimens to generate personalized insights in under 7 days. This is complemented by the Metastasis-on-a-Chip platform (NASA InSPA funded) for microgravity-based cancer metastasis modeling, and the Automated Chemotherapy Selection Platform (NSF SBIR funded) for pancreatic and colorectal cancers. The company also provides services for pharmaceutical companies, clinicians, and patients, leveraging space-based research through ISS experiments to enhance the biological fidelity of their tumor models.

Differentiator

Problem solved

Functional benefit

Products and services

  • Automated Tumor-on-a-Chip Platform End-to-end automated microfluidic platform that cultures patient-derived microtumors from biopsy or surgical specimens and screens them against 50+ FDA-approved and investigational chemotherapeutic regimens to produce personalized response profiles within 7 days; sold to pharmaceutical companies for preclinical screening and to oncology providers for personalized chemotherapy selection.
  • Personalized Chemotherapy Selection Service Clinical service in which Encapsulate receives a patient's tumor specimen, screens it against the chemotherapeutic library on the tumor-on-a-chip platform, and returns a ranked, patient-specific treatment response profile to inform the treating oncologist's regimen selection.
  • Pharmaceutical Preclinical Drug Screening Service Service for pharmaceutical R&D teams in which Encapsulate runs investigational and approved oncology compounds through patient-derived microtumors on the tumor-on-a-chip platform, delivering preclinical efficacy, dose-response, and lead-optimization data with reduced turnaround compared to manual organoid workflows.
  • Metastasis-on-a-Chip Microgravity Research Program Research program that extends the tumor-on-a-chip platform into microgravity conditions aboard the International Space Station to study tumor metastasis and behavior in a uniquely low-shear environment, offered to academic, translational, and pharmaceutical partners studying metastasis and drug resistance.

Quantifiable outcome

  • Personalized treatment recommendations delivered in under 7 days
  • +5 more outcomes

Companies that use Encapsulate

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Encapsulate technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Encapsulate partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Space TangocoreStrategic or Co-development Partner · 8 July 2025In-orbit implementation partner for deploying and operating experiments aboard the International Space Station. Marks their third mission together. Space Tango provides flight implementation services for Encapsulate's automated biochip platform for space-based cancer research.
  • Moffitt Cancer CentercoreStrategic or Co-development Partner · 1 July 2025Clinical partner for retrospective and prospective clinical studies in pancreatic and colorectal cancers as part of NSF SBIR Phase II grant. Key investigators include Dr. Tiago Biachi and Dr. Sarah Hoffe.
  • Memorial Sloan Kettering Cancer Center (MSKCC)coreStrategic or Co-development Partner · 1 July 2025Clinical partner for retrospective and prospective clinical studies in pancreatic and colorectal cancers. Dr. Danny Khalil serves on Clinical Advisory Board.
  • UConn HealthcoreStrategic or Co-development Partner · 1 July 2025Primary clinical partner and headquarters location. Hosts Encapsulate in Technology Incubation Program. Dr. John Birk serves on Clinical Advisory Board.
  • MassChallenge BostoncoreStrategic or Co-development Partner · 1 January 2019Selected into 2019 MassChallenge Boston program as one of top 9% of applicants worldwide. Zero-equity startup accelerator providing mentorship, corporate partners, and co-working space.
  • NASAcoreStrategic or Co-development PartnerNASA provides access to microgravity environments through the International Space Station and supports through programs like In Space Production Applications (InSPA). NASA awarded $3.63M InSPA Phase 1 grant for Metastasis-on-a-Chip development.
  • International Space Station National Laboratory (ISSNL)coreStrategic or Co-development PartnerISSNL provides access to the ISS for microgravity research and has featured Encapsulate's work multiple times. Encapsulate launched cargo to the ISS aboard SpaceX CRS-30 mission.
  • Hartford HealthCarecoreStrategic or Co-development PartnerClinical partner and founding partner of Digital Health CT accelerator. Dr. Alvaro Menendez serves on Clinical Advisory Board. Partnered for clinical validation studies.
  • BoeingcoreStrategic or Co-development PartnerCo-sponsor of Technology in Space Prize with ISS National Lab. Boeing and ISS NL have collectively awarded 27 projects and more than $4.5 million through the prize since 2012.
  • Yale Biomedical EngineeringminorStrategic or Co-development PartnerDr. Andre Levchenko serves on Scientific Advisory Board, providing academic expertise in biomedical engineering.
  • Digital Health CT AcceleratorcoreStrategic or Co-development PartnerMedTech accelerator program in Hartford with founding partners including Hartford HealthCare, Trinity College, UConn School of Business and Technology Commercialization Services, and CTNext.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Encapsulate competitors and assessment

Company assessment

Direct peers

  • Mimetas: Dutch organ-on-a-chip company providing microfluidic 3D cell culture platforms including tumor models for drug screening. Comparable technology architecture and pharma services orientation.
  • Certis Oncology Solutions: Functional precision oncology company providing patient-derived tumor models for drug response prediction and preclinical services. Direct overlap in ex vivo chemo-response testing services.
  • TissUse: Multi-organ-chip company developing microphysiological systems for preclinical testing. Comparable microfluidic platform with broader multi-organ emphasis, including oncology-relevant applications.
  • Emulate, Inc. Leader in organ-on-a-chip technology for drug discovery and disease modeling, including cancer applications. Directly comparable in core microfluidic organoid platform approach, though broader in tissue types and with deeper commercial scale.
  • Champions Oncology: Provider of patient-derived xenograft models and tumor-based services for personalized oncology and pharma R&D. Adjacent approach (in vivo PDX) competing for the same functional precision oncology and preclinical services budget.
  • Kiyatec: Functional precision oncology company using 3D patient-derived cell culture to predict cancer therapy response ex vivo. Most direct competitor in the patient-derived tumor organoid chemo-response prediction space Encapsulate targets.
  • CN Bio: Organ-on-a-chip and microphysiological systems provider for preclinical drug development. Competes in the same microfluidic organoid platform category with pharma R&D customers.

Emerging players

  • Recursion Pharmaceuticals: AI-enabled biology platform combining high-throughput experimentation with machine learning for drug discovery. Comparable in applying AI/ML to biological data, though focused upstream on therapeutic discovery rather than patient diagnostics.
  • Hurel Corporation: Microfluidic cell-based assay technology company serving preclinical drug development with emphasis on liver and oncology applications. Comparable microfluidic technology and pharma services customers.

Broad incumbents

  • Charles River Laboratories: Large preclinical CRO offering extensive oncology drug development and patient-derived model services. Incumbent player in the same pharma services budget, with broader portfolio and established scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Encapsulate social profiles

Digital presence

Encapsulate financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Encapsulate leadership team

Management profile

Number of profiles

Profiles11 records

Encapsulate funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Encapsulate M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Encapsulate

What does Encapsulate do?

Encapsulate develops an automated tumor-on-a-chip platform that grows patient-derived microtumors from biopsy or surgical specimens and screens them against clinical treatment regimens to produce patient-specific chemotherapy response profiles. The platform is also offered to pharmaceutical companies for preclinical drug efficacy and lead-optimization studies, and supports a novel microgravity-based metastasis research program on the International Space Station. End-to-end turnaround for clinical response profiles is delivered in under 7 days, with screening capability spanning 50+ FDA-approved and investigational chemotherapeutic agents.

Is Encapsulate a public or private company?

Encapsulate is a private company. It is classified as venture growth investor backed and is currently operating.

When was Encapsulate founded?

Encapsulate was founded in 2019. It employs 11 to 50 people.

Where is Encapsulate based?

Encapsulate is headquartered in Farmington, United States, in the North America region.

How does Encapsulate make money?

Four revenue lines are on record. Pharmaceutical Drug Testing Services are the primary driver. The others are clinical Testing Services, government Research Grants and biobank and Data Services.

Who are Encapsulate's main competitors?

Direct peers on record are Mimetas, Certis Oncology Solutions, TissUse, Emulate, Inc., Champions Oncology, Kiyatec and CN Bio. Emerging players are Recursion Pharmaceuticals and Hurel Corporation. Charles River Laboratories is listed as a broad incumbent.

Does Encapsulate have an API?

No public API is recorded for Encapsulate.

What industry is Encapsulate in?

Encapsulate's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsExploring Precision Medicine For Pancreatic CancerUConn School of Medicine is collaborating with Encapsulate, Inc. to test the company's Biochip System for personalized pancreatic cancer treatment. The research aims to validate whether the system can predict effective chemotherapy regimens by analyzing patient tumor tissue samples in a laboratory setting.BenzingaNanoNest Announces AI-Powered Smart Home Technology for Its Modular Housing PlatformNanoNest Homes announced AI-powered smart home technology for its modular housing platform, targeting a first release by end of 2026. The system includes AI brain, security, energy management, and connected controls, with homes starting at $149,000. The company is raising capital via Regulation CF to fund development and scale.PR NewswireYour Tumor's Best Treatment? A Space-Based Test Could Tell YouEncapsulate is using the ISS to test patient tumor samples against drugs, with a $3.63 million NASA grant and $1.25 million NSF award. The system grew 3D tumor models in microgravity, revealing drug responses not seen on Earth. A clinical study with 100-200 colorectal and pancreatic cancer patients is underway.AInvestThe Rise of Space-Driven Biotechnology: How ISS Research is Fueling the Next Wave of Health InnovationsThe ISS National Lab is accelerating biotech innovation through microgravity research, with startups like Encapsulate and Sierra Space developing drug platforms and organoid incubators. Startups in the ISS ecosystem have collectively raised $2.4 billion post-spaceflight, signaling commercial viability. Investors are advised to prioritize companies developing scalable space infrastructure and microgravity-enabled drug platforms.EncapsulateEncapsulate Awarded $1.25M NSF SBIR Phase II Grant to Advance Automated Chemotherapy Selection Platform for Pancreatic and Colorectal CancersEncapsulate, Inc. received a $1.25 million NSF SBIR Phase II grant to advance its automated biochip platform for personalized cancer treatment. The funding will support clinical studies in pancreatic and colorectal cancers, with validation at UConn Health, Moffitt, MSKCC, and Hartford HealthCare.PR NewswireSpace-Made Fibers and Novel Biotech Among Research Returning to Earth After Successful Space Station MissionSpaceX's Dragon capsule from the 30th Commercial Resupply Services mission returned to Earth off the Florida coast on April 30, 2024, carrying nearly 565 pounds of research payloads sponsored by the ISS National Laboratory after more than 35 days onboard the International Space Station. The returning investigations include space-manufactured ZBLAN optical fiber (Flawless Photonics produced over 7 miles of fiber in microgravity), novel biotech such as Oculogenex's gene therapy for age-related macular degeneration, Encapsulate's tumor-on-a-chip cancer screening system, and LambdaVision's layer-by-layer artificial retina manufacturing. The space-drawn materials will undergo independent analysis to determine if they have superior performance characteristics compared to terrestrial production.